These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 39775)

  • 1. [Effect of preparations that alter catecholaminergic processes on the serotoninergic syndrome of head twitching in mice].
    Shchelkunov EL
    Farmakol Toksikol; 1979; 42(5):470-4. PubMed ID: 39775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of repeated administration of imipramine, citalopram and mianserin on responsiveness of central serotonergic, alpha 2-adrenergic and cholinergic system in mice.
    Maj J; Rogóz Z; Skuza G; Sowińska H
    Pol J Pharmacol Pharm; 1989; 41(4):313-9. PubMed ID: 2561380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist.
    Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E
    Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions.
    Arnt J; Hyttel J; Overø KF
    Pol J Pharmacol Pharm; 1984; 36(2-3):221-30. PubMed ID: 6591152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On some relationships between dopaminergic and serotoninergic mechanisms in pentylenetetrazol convulsions in albino mice.
    Lazarova M; Roussinov K
    Acta Physiol Pharmacol Bulg; 1979; 5(3):67-74. PubMed ID: 317212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that serotonin mediates some behavioral effects of amphetamine.
    Sloviter RS; Drust EG; Connor JD
    J Pharmacol Exp Ther; 1978 Aug; 206(2):348-52. PubMed ID: 308099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Functional role of noradrenergic neurons in the hypothermic effect of apomorphine and other dopaminomimetics].
    Shchelkunov EL; Andreeva OG; Korovin KF; Ostroumova MN
    Farmakol Toksikol; 1980; 43(5):558-63. PubMed ID: 7449984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of neuroleptics with central dopamine and noradrenaline receptor blocking properties in the L-DOPA and (+)-amphetamine-induced waking EEG in the rat.
    Monti JM
    Br J Pharmacol; 1979 Sep; 67(1):87-91. PubMed ID: 40644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some central effects of tiflucarbine, a new potential antidepressant drug.
    Maj J; Rogóz Z; Sowińska H; Zalewski Z
    Pol J Pharmacol Pharm; 1987; 39(1):63-74. PubMed ID: 2823240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in the sensitivity of brain dopamine and serotonin receptors during the prolonged administration of carbidine].
    Zharkovskiĭ AM; Chereshka KS; Zharkovskaia TA; Allikmets LKh
    Biull Eksp Biol Med; 1985 Dec; 100(12):719-22. PubMed ID: 2866801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
    Hertel P; Nomikos GG; Svensson TH
    Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological analysis of the effect of homovanillic acid on rat behavior].
    Zharkovskiĭ AM; Klejnrok Z
    Farmakol Toksikol; 1981; 44(4):400-3. PubMed ID: 7286195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central effects of Ro 19-6327 given acutely and repeatedly.
    Skuza G; Rogóz Z
    Pol J Pharmacol Pharm; 1991; 43(6):437-47. PubMed ID: 1668212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.